Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life
Research output: Contribution to journal › Article › peer-review
Authors
Colleges, School and Institutes
Abstract
Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.
Details
| Original language | English |
|---|---|
| Pages (from-to) | 3188-94 |
| Number of pages | 7 |
| Journal | Journal of Clinical Oncology |
| Volume | 17 |
| Issue number | 10 |
| Publication status | Published - Oct 1999 |
Keywords
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Ifosfamide, Lung Neoplasms, Male, Middle Aged, Mitomycin, Prognosis, Quality of Life, Survival Analysis